D-314(D-314) - 药物靶点：GIPR x GLP-1R_在研适应症：2型糖尿病，肥胖_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点

GIPR x GLP-1R

作用机制

GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病肥胖

非在研适应症-

原研机构

上海多米瑞生物技术有限公司

在研机构

上海多米瑞生物技术有限公司

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 D-314 相关的临床结果

登录后查看更多信息

100 项与 D-314 相关的转化医学

登录后查看更多信息

100 项与 D-314 相关的专利（医药）

登录后查看更多信息

1

项与 D-314 相关的文献（医药）

2024-12-31·Hematology

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center

Article

作者: Wang, Li ; Chen, Juan ; Wan, Yan ; Zhang, Xingxia ; Bian, Meiru ; Si, Yejun ; Yang, Xiaotian ; Huang, Sailan ; Zhang, Yanming ; Hao, Ziyi ; Fei, Yingying ; Zhang, Bing ; Yu, Youhuan ; Lin, Guoqiang

OBJECTIVESRelapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.METHODSA total of eight patients with R/R B-ALL were enrolled in the study from November 2021 to August 2022. All patients received chemotherapy based on a combination regimen of venetoclax and azacitidine. The regimen was as follows venetoclax 100 mg d₁, 200 mg d₂, 400 mg d_3-14, azacitidine 75 mg/m² d_1-7.RESULTSFive of eight patients achieved very deep and complete remission (CR) with minimal residual disease (MRD) less than 0.1%. One patient achieved partial remission. Two patients did not achieve remission. There were no serious adverse events and all patients were well tolerated. Three patients were eligible for consolidation chemotherapy and were bridged to CAR-T therapy.CONCLUSIONSThe combined regimen of venetoclax and azacitidine may be beneficial for patients with R/R B-ALL.

100 项与 D-314 相关的药物交易

登录后查看更多信息